Author

K. Litchfield

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 8

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 7 Approach:experimental assay· 5 Research Focus:cancer & tumor microenvironment· 4 Approach:statistical model· 4 Assay:bulk RNA-seq· 3 Research Focus:differential expression· 3 Research Focus:drug response / drug discovery· 3 Research Focus:cell type annotation· 2

Frequent Co-Authors

C. Swanton· 4 shared N. McGranahan· 2 shared S. A. Quezada· 2 shared S. Turajlic· 2 shared A. A. Hakimi· 1 shared A. A. Kolodziejczyk· 1 shared A. A. Schaffer· 1 shared A. Amirthanayagam· 1 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

C. Swanton

Mutual co-authors in cluster

Author profile →

8 papers

Recent·Most cited

CRISPR/Cas9 screen identifies KRAS-induced COX-2 as a driver of immunotherapy resistance in lung cancer

J. Boumelha, A. de Castro, N. Bah, H. Cha, S. de Carne Trecesson, S. Rana, P. Anastasiou, E. Mugarza, C. Moore, R. Goldstone, P. East, K. Litchfield, S.-H. Lee, M. Molina-Arcas, J. Downward

The paper identifies KRAS-induced COX-2 as a driver of immunotherapy resistance in lung cancer through CRISPR/Cas9 screening and shows targeting COX-2 enhances immune checkpoint blockade efficacy.

bioRxiv · Apr 13, 2023Cancer Biology

Genomic evolution of non-small cell lung cancer patient-derived xenograft models

R. E. Hynds, A. Huebner, D. R. Pearce, A. U. Akarca, D. A. Moore, S. Ward, K. H. C. Gowers, T. Karasaki, M. S. Hill, M. Al Bakir, G. A. Wilson, O. Pich, M. Sivakumar, A. Ben Aissa, E. Gronroos, , C. Swanton

This study examines how well PDX models capture intratumour heterogeneity in NSCLC, finding that most models originate from a single subclone but regional models can capture diversity.

bioRxiv · Jan 6, 2023Cancer Biology

Mutation Rate Evolution Drives Immune Escape In Mismatch Repair-Deficient Cancer

H. Kayhanian, P. Barmpoutis, E. Lakatos, W. C. H. Cross, G. Caravagna, L. Zapata, K. Litchfield, C. D. Steele, W. Waddingham, D. Patel, S. Milite, C. Jin, A.-M. Baker, C. Ross, D. Alexander, , M. Jansen

The paper shows that mutation rate adaptation in MMRd cancers drives immune escape by modulating neoantigen diversity and subclonal mutation rates.

bioRxiv · Mar 6, 2022 · PreprintCancer Biology

The proteasome regulator PSME4 drives immune evasion and abrogates anti-tumor immunity in NSCLC

A. Javitt, M. D. Shmueli, M. P. Kramer, A. A. Kolodziejczyk, I. J. Cohen, I. Kamer, K. Litchfield, E. Bab-Dinitz, O. Zadok, V. Neiens, A. Ulman, L. Radomir, H. Wolf-Levy, A. Eisenberg-Lerner, A. Kacen, , Y. Merbl

This paper identifies PSME4 as a proteasome regulator that suppresses anti-tumor immunity in NSCLC by inhibiting immunoproteasome activity and antigen presentation.

bioRxiv · Oct 24, 2021 · PreprintCancer Biology

Immune determinants of the association between tumor mutational burden and immunotherapy response across cancer types

N. Sinha, S. Sinha, C. V. Mayor, A. A. Schaffer, K. Aldape, K. Litchfield, T. Chan, L. G. T. Morris, E. Ruppin

The paper investigates how immune factors influence the predictive power of tumor mutational burden (TMB) for immunotherapy response across cancer types.

bioRxiv · May 25, 2021Cancer Biology

9p21 Loss Defines the Evolutionary Patterns of Aggressive Renal Cell Carcinomas

F. Carbone, J. K. Huang, L. Perelli, E. Del Poggetto, T. Gutschner, H. Tomihara, M. Soeung, T. N. A. Lam, R. Xia, C. Zhu, X. Song, J. Zhang, K. Sircar, G. G. Malouf, A. Sgambato, , G. Genovese

This study establishes a mouse model of renal cell carcinoma showing that 9p21 loss drives aggressive tumor evolution with chromosomal instability and metastasis.

bioRxiv · Nov 3, 2020 · PreprintCancer Biology

Somatic chromosomal number alterations affecting driver genes inform in-vitro and clinical drug response in high-grade serous ovarian cancer

F. Correia Martins, D.-L. Couturier, I. Santiago, C. Sauer, M. Vias, M. Angelova, D. Sanders, A. Piskorz, J. Hall, K. Hosking, A. Amirthanayagam, S. Cosulich, L. Carnevalli, B. Davies, T. B. K. Watkins, , J. D. Brenton

This study shows that somatic copy number alterations in driver genes correlate with drug response in HGSOC spheroid models and clinical settings.

bioRxiv · Oct 4, 2020 · PreprintCancer Biology

Escape from nonsense mediated decay associates with anti-tumor immunogenicity

K. Litchfield, J. Reading, E. Lim, H. Xu, P. Liu, M. Al-Bakir, S. Wong, A. Rowan, S. Funt, T. Merghoub, M. Lauss, I. M. Svane, G. Jonsson, J. Herrero, J. Larkin, , C. Swanton

This study identifies NMD-escape fs-indels as a biomarker associated with improved response to immunotherapy in melanoma patients.

bioRxiv · Nov 14, 2019Cancer Biology